Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Research & Clinical Trials > Study Search Tool > A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

This study is open to:

Men and women who meet the following family/age criteria:

  • Two or more relatives with pancreatic cancer on the same side of the family. where at least one affected relative is a first degree relative (FDR). (Additional criteria may be required) (Participant must be ≥50 years old OR 10 years younger than the age of onset of relative).
  • Anyone with an inherited mutation in BRCA1, BRCA2, PALB2, ATM with one FDR or secondary degree related (SDR) with pancreatic cancer (Participant must be ≥50 years old OR 10 years younger than the age of onset of relative).
  • Familial atypical multiple mole-melanoma with an inherited mutation in: p16, CDKN2A (Participant must be ≥50 years old)
  • Known mutation carrier for STK11 (Peutz Jeghers Syndrome) (Participant must be ≥35 years old)
  • Lynch syndrome (HNPCC) with inherited mutation in: MLH1, MSH2, MSH6, PMS2, or EPCAM + one FDR or SDR with PDAC (Participant must be ≥50 years old OR 10 years younger than the age of onset of relative).
  • Hereditary pancreatitis with PRSS1 pathogenic history of pancreatitis (Participant must be ≥40 years old).

Additional criteria may apply. See study listing on clinicaltrials.gov

This study is not open to:

Anyone who does not meet inclusion criteria listed above. 

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Clinicaltrials.gov identifier:
NCT03693378

Prevention:
Pancreatic

Study Contact Information

For additional information, please contact: Cindy Callahan, RN by email or Susanne Glantz by email.

 


 

About the Study

This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.

Type of Study

This study will enroll people who do not have pancreatic cancer, but have a higher risk of developing the disease. This is a prospective study, which will watch participants for development of pancreatic cancer over time.

What the Study Entails

  • Participants will have blood samples taken and tested using the IMMray PanCan-d test.
  • Participants will also undergo imaging and doctors visits consistent with the research site's pancreatic cancer screening program.
  • The analysis will compare IMMray PanCan-d test results for each subject to corresponding imaging assessments performed as part of standard of care pancreatic screening surveillance.
  • Any subject who shows evidence of disease while on-study will be removed from the study to receive standard of care per the hospital's guidelines.

Study Sites

United States

  • Connecticut
    • New Haven, CT: Yale University
  • Illinois
    • Chicago, IL: University of Chicago Medical Center
  • Massachusetts
    • Boston, MA: Massachusetts General Hospital
    • Worcester, MA: University of Massachusetts 
      • Contact: Giles Whalen by email        
  • New York
    • New York, NY: New York University Hospital
    • New York, NY: Columbia University   
      • Contact: Fay Kastrinos, MD by email         
    • New York, NY: Mount Sinai Hospital
  • Oregon
    • Portland, OR: Oregon Health & Science University
      • Contact: Brett Sheppard by email      
  • Pennsylvania
    • Philadelphia, PA: University of Pennsylvania
    • Pittsburgh, PA: University of Pittsburgh Medical Center
    • Contact: Randall Brand by email   

Canada

  • Quebec
    • Montreal: The Research Institute of the McGill University Health Centre

Other international sites are open in the following countries:

  • Spain
  • Sweden
  • United Kingdom     

Principal Investigator

Study Director: Rolf Ehrnström Immunovia, Inc.

FORCE:Facing Our Risk of Cancer Empowered